Aurora Spine Corporation Announces Newly Published Paper on Need for a Bone Mineral Density-Matched Interbody Cage
December 21 2021 - 6:00AM
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:
ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative
medical devices that improve spinal surgery outcomes, announced
today that a Peer-Reviewed Clinical Publication titled ‘Improving
the Management of Patients with Osteoporosis Undergoing Spinal
Fusion: The Need for a Bone Mineral Density-Matched Interbody Cage,
was published in Orthopedic Research and Reviews.
The research article provides an introductory profile of a
spinal interbody implant designed to simulate the lattice structure
of human cancellous bone, with a similar modulus of elasticity, and
specialized to match a patient’s bone status across the bone
mineral density (BMD) continuum. The implant incorporates an open
pore design where the degree of pore compactness directly
corresponds to the patient’s dual x-ray absorptiometry
(DXA)-defined BMD status, including patients with osteoporosis. An
implant that fits this criterion is Aurora’s DEXA TiBone™ (also
known as DEXA-C), a spinal interbody implant that received 510(k)
premarket notification for commercial use in the US in August 2021.
"The development of an interbody device that is matched to the
patient’s bone density is truly the future of ensuring
improved outcomes for patients with spinal implants,” said Steven
Falowski, M.D., Director of Functional Neurosurgery at
Argires-Marotti Neurosurgical Associates of Lancaster,
PA. “It addresses a gap we have had in ensuring bony
fusion following spinal surgery. This technology is
adaptable to multiple points of intended fusion in the body and
will surely be one of the most valuable tools in a surgeon's
armamentarium."
Dr. Sebastian Koga, MD, FAANS, Chairman of Neurosurgery and
Medical Director of the Ochsner Neuroscience Institute for the
Ochsner North Shore Region, stated, “The DEXA-C implant is the
beginning of personalized medicine in spine surgery. I anticipate
that it will allow us to operate on older patients with lower bone
densities, while improving fusion rates and overall outcomes. We
will be hearing a lot more about this technology in the years
ahead.”
Jon Block PhD, an independent clinical consultant, stated, “This
research article highlights the clinically important, but often
unappreciated, link between the concurrent rising prevalence of
both spinal degenerative disease and osteoporosis.
Consequently, developing interbody devices that are bioengineered
specifically to “adapt” to differing bone mineral density
environments provides surgeons with a wider array of options for
treating patients across the entire range of DEXA values."
Trent Northcutt, President and CEO of Aurora Spine stated, “This
research article initiates the discussion that is required in the
industry to deliver customized implants to match a patient’s bone
density. We are pleased by the publication of this article as
Aurora’s DEXA technology platform offers customized implants to
match a patient’s bone density and to promote improved fusion and
bone growth. Aurora believes in this approach, as many patients
that undergo certain spine and orthopedic procedures are part of an
aging population and are experiencing some form of osteoporosis,
which can complicate spinal fusion procedures and cause
post-operative issues. That’s why we’ve created the DEXA platform
and are planning on continued research and studies on our first
approved product, the DEXA-C, which is expected to be implanted in
its first procedure in the coming weeks.”
A copy of the Peer-Reviewed Clinical Publication can be found at
https://dexaimplants.com.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal
implant market through a series of innovative, minimally invasive,
regenerative spinal implant technologies. Additional information
can be accessed at www.aurora-spine.com or
www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release
includes information concerning the proposed use and success of the
company’s products in surgical procedures. Aurora Spine cautions
investors of Aurora Spine's securities about important factors that
could cause Aurora Spine's actual results to differ materially from
those projected in any forward-looking statements included in this
news release. Any statements that express, or involve discussions
as to, expectations, beliefs, plans, objectives, assumptions or
future events or performance are not historical facts and may be
forward-looking and may involve estimates, assumptions and
uncertainties which could cause actual results or outcomes to
differ unilaterally from those expressed in such forward-looking
statements. No assurance can be given that the expectations set out
herein will prove to be correct and, accordingly, prospective
investors should not place undue reliance on these forward-looking
statements. These statements speak only as of the date of this
press release and Aurora Spine does not assume any obligation to
update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
asapf@lythampartners.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
From Apr 2023 to Apr 2024